Form 4 for CTMX CytomX Therapeutics, Inc.
Accepted 2025-06-17 00:00:00 ET · period of report 2025-06-13 · accession 0001610717-25-000235 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-06-17 | 2025-06-13 | CTMX | BELVIN MARCIA | SVP, CSO | M - OptEx | $0.00 | +37.5K | 286.1K | +15% | $0 |
| D | 2025-06-17 | 2025-06-16 | CTMX | BELVIN MARCIA | SVP, CSO | S - Sale+OE | $2.69 | -13.9K | 272.3K | -5% | -$37.3K |
| D | 2025-06-17 | 2025-06-13 | CTMX | BELVIN MARCIA | SVP, CSO | M - OptEx | $0.00 | -37.5K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-06-13 | M | A | 37,500 | $0.00 | 286,136 | D | — | — | (F2) Includes 158,958 restricted stock units. |
| 2 | Common | Common Stock | 2025-06-16 | S | D | 13,884 | $2.69 | 272,252 | D | — | — | (F2) Includes 158,958 restricted stock units. |
| 3 | Derivative | Performance Stock Units | 2025-06-13 | M | D | 37,500 | $0.00 | 0 | D | — · — to — | 37,500 Common Stock | (F4) Each PSU represented a contingent right to receive one (1) share of common stock upon vesting. |